Avoidant/Restrictive Food Intake Disorder (ARFID) is a feeding and eating disorder introduced in DSM-5 and retained in DSM-5-TR, defined by clinically significant restriction of food intake that is not driven by concerns about weight, shape, or body image. It commonly presents in childhood but is increasingly recognized across the lifespan, and it sits at the crossroads of psychiatry, pediatrics, gastroenterology, and feeding therapy. Three non-exclusive clinical drivers organize the phenotype: low interest in eating, sensory-based avoidance, and fear of aversive consequences such as choking or vomiting. The differential turns on a single discriminating question — is the restriction motivated by weight or shape concerns? — which separates ARFID from Anorexia nervosa. Untreated, ARFID produces weight loss or faltering growth, nutritional deficiencies, dependence on enteral feeds or oral supplements, and impaired psychosocial functioning. The clinical bottom line: recognize it early, screen for medical compromise, and route to a feeding-disorder-literate team because most generic eating-disorder pathways were not built for this population.

ARFID is the youngest of the feeding and eating disorders in DSM nomenclature, and population estimates remain provisional. What is consistent across studies is that ARFID is not rare in pediatric feeding clinics and eating-disorder programs, and that its demographic shape differs from anorexia nervosa.^1-2

Prevalence and incidence

• Community prevalence in children and adolescents is estimated at roughly 0.3-3%, with higher rates in clinical samples drawn from feeding and eating-disorder services.^1,3
• ARFID accounts for 5-22% of new presentations to specialist pediatric eating-disorder programs.^2,4
• Lifetime prevalence in adults is less well established; survey data suggest figures under 1%, but underdetection is likely because adult eating-disorder services rarely screen for non-weight-driven restriction.^1,5

Age and sex

• Onset is typically in early to middle childhood, often with a long history of selective or fearful eating predating diagnosis.^1,3
• Compared with anorexia nervosa, ARFID skews younger at presentation and shows a more balanced sex ratio, with boys representing a substantially larger share than in restrictive anorexia nervosa.^2,4
• A subset of patients present in adolescence or adulthood after a triggering event such as a choking episode, severe gastroenteritis, or food poisoning.^1,6

Comorbidity

• Neurodevelopmental conditions are over-represented; autism spectrum disorder and ADHD are the most consistent associations, with autism prevalence in ARFID cohorts reported in the 10-30% range.^2,4,7
• Anxiety disorders, particularly generalized anxiety disorder, specific phobia, and obsessive-compulsive disorder, are common.^2,4
• Functional gastrointestinal disorders and disorders of gut-brain interaction frequently co-occur and can both precipitate and perpetuate the eating pattern.^6,8
• Suicidality rates appear lower than in anorexia or bulimia nervosa but are not negligible, particularly in adolescents with chronic illness burden.^2,4

Risk factors

• Early feeding difficulties, prematurity, congenital anomalies of the aerodigestive tract, and tube-feeding history.^3,6
• Sensory hyperreactivity, including in the context of autism spectrum disorder.^2,4,7
• Anxious temperament and parental anxiety disorders.^1-2
• Discrete aversive feeding event (choking, vomiting, allergic reaction) as a trigger for fear-based subtype.^1,6

ARFID is best understood as a heterogeneous phenotype produced by interacting neurobiological, sensory, and learning-based mechanisms rather than a single disease. Current models map the three clinical drivers (low interest, sensory sensitivity, fear of aversive consequences) onto partially distinct mechanistic substrates.^1,9

Neurobiological substrates

• Low-interest presentations may involve blunted homeostatic and hedonic appetite signaling, with proposed contributions from hypothalamic and mesolimbic circuits and altered ghrelin/leptin dynamics; the human data are preliminary.^9-10
• Sensory-based avoidance maps onto sensory processing differences seen in autism spectrum disorder, including hyperreactivity in olfactory, gustatory, and tactile-oral domains.^7,9
• Fear-based presentations recruit threat-learning circuitry (amygdala, insula, anterior cingulate), with the classic features of acquired food aversion after a conditioning event.^9,11

Genetics

• Heritability estimates for ARFID from twin studies are high, in the range reported for other eating disorders, but data remain limited.¹²
• Familial aggregation of selective eating, anxiety disorders, and autism spectrum disorder is observed but no specific risk loci have been confirmed.^7,12

Environmental and learning factors

• Operant conditioning around mealtime distress can entrench avoidance, particularly when caregivers escalate accommodation in response to refusal.^3,9
• Early medical experiences such as nasogastric feeding, repeated airway suctioning, or painful reflux can establish oral aversion that persists after the underlying condition resolves.^3,6
• A discrete choking or vomiting episode can produce one-trial fear learning that generalizes to entire food categories.^1,11

Integrative model

• The dominant working model is a three-driver framework in which sensory sensitivity, low appetitive drive, and threat-based aversion each contribute, often in combination, to clinically significant restriction.^1,9
• Medical sequelae (weight loss, micronutrient deficiency, delayed gastric emptying from chronic undernutrition) feed back to worsen appetite and tolerance, sustaining the disorder.^6,9

DSM-5-TR places ARFID in the Feeding and Eating Disorders chapter alongside anorexia nervosa, bulimia nervosa, and binge-eating disorder. The criteria are intentionally broad to capture a heterogeneous phenotype while preserving a clear boundary from weight-and-shape-driven eating disorders.¹³

DSM-5-TR criteria

• Criterion A: An eating or feeding disturbance (such as apparent lack of interest in food, avoidance based on sensory characteristics, or concern about aversive consequences of eating) producing persistent failure to meet appropriate nutritional or energy needs, with at least one of the following — significant weight loss or faltering growth, significant nutritional deficiency, dependence on enteral feeding or oral nutritional supplements, or marked interference with psychosocial functioning.¹³
• Criterion B: The disturbance is not better explained by lack of available food or by a culturally sanctioned practice.¹³
• Criterion C: The disturbance does not occur exclusively during anorexia nervosa or bulimia nervosa, and there is no evidence of a disturbance in the experience of body weight or shape.¹³
• Criterion D: The disturbance is not attributable to a concurrent medical condition or better explained by another mental disorder; when it occurs in the context of another condition, it exceeds what would be expected and warrants independent clinical attention.¹³

Specifiers and course

• DSM-5-TR does not specify formal severity grades for ARFID, in contrast to anorexia nervosa.¹³
• In remission is the recognized course specifier, applied when full criteria were previously met but have not been met for a sustained period.¹³
• Clinical convention is to describe the predominant driver(s) — low interest, sensory, fear of aversive consequences — though these are not formal DSM specifiers.^1,9

ICD-11 differences

• ICD-11 includes ARFID under feeding and eating disorders (6B83) with conceptually similar criteria.¹⁴
• ICD-11 retains a separate category for pica and rumination-regurgitation disorder, paralleling DSM-5-TR.¹⁴
• Neither system requires a specific weight or BMI threshold; functional and nutritional impairment is sufficient.^13-14

ARFID looks different from anorexia nervosa at the bedside, and the differences matter for both diagnosis and treatment. Restriction is longstanding, often present from early childhood, and the patient typically frames the problem around the food rather than around the body.^1,3

Three-driver phenotype

• Low interest in eating: the patient forgets to eat, becomes full quickly, finds eating effortful, or describes food as unrewarding; weight loss is often gradual and unintended.^1,9
• Sensory-based avoidance: rejection based on texture, smell, temperature, color, or brand; the accepted food list is narrow and stable for years, with new foods triggering distress.^1,4
• Fear of aversive consequences: avoidance after a choking, vomiting, allergic, or pain episode, with anticipatory anxiety, hypervigilance for bodily sensations during eating, and avoidance of textures or settings associated with the index event.^1,11

Course and prototypical presentation

• Pediatric presentation: a young child with a chronically narrow diet (often fewer than 20 accepted foods), faltering growth, and family meals dominated by accommodation.^3-4
• Adolescent presentation: an early teen with longstanding selectivity who decompensates when accepted foods become unavailable (camp, school change, brand reformulation) or after an acute illness.^1,4
• Adult presentation: chronic selective eating now causing micronutrient deficiency, social impairment, or comorbid disorders of gut-brain interaction; or a post-event fear-based presentation in a previously well adult.^5-6

Red flags requiring urgent attention

• Bradycardia, hypotension, orthostatic instability, or hypothermia indicating medical instability.^6,15
• Rapid weight loss or BMI/z-score below 75% of expected, especially in children.^6,15
• Vitamin deficiency syndromes — scurvy from vitamin C deficiency, optic neuropathy or peripheral neuropathy from B12 or thiamine deficiency, rickets from vitamin D deficiency.^6,16
• Refusal of all oral intake or progressive narrowing to fewer than three foods.^6,15

The differential for ARFID is broad because the presenting complaint — not eating enough — is non-specific. The discriminating questions are about motivation (weight/shape concern?), trajectory (longstanding vs. acute?), and medical findings (organic cause?).^1,13

Anorexia nervosa

• Anorexia nervosa requires fear of weight gain or persistent behavior interfering with weight gain, plus disturbance in body-image experience.¹³
• ARFID restriction is driven by sensory, appetitive, or fear-of-consequence mechanisms with no body-image disturbance.^1,13
• Mixed presentations occur, particularly in adolescent girls with longstanding selective eating who later develop weight concerns; the diagnosis follows the dominant current driver.^2,4

Other psychiatric disorders

• Major depressive disorder: appetite loss is a depressive symptom and does not warrant a separate ARFID diagnosis unless restriction substantially exceeds what depression explains.¹³
• Specific phobia of vomiting (emetophobia): overlap with fear-based ARFID; ARFID is diagnosed when the food restriction itself causes the impairment.^1,13
• Obsessive-compulsive disorder with contamination concerns: distinguished by the presence of obsessions and compulsions and by avoidance pattern.¹³
• Psychotic disorders with food-related delusions (e.g. paranoia of poisoning): the underlying psychosis takes diagnostic precedence.¹³
• Autism spectrum disorder: sensory-based selective eating is common; a separate ARFID diagnosis is added when restriction produces the Criterion A consequences and warrants independent clinical attention.^7,13

Medical mimics to exclude

• Gastrointestinal: eosinophilic esophagitis, achalasia, gastroparesis, celiac disease, inflammatory bowel disease, peptic ulcer disease.^6,8
• Endocrine and metabolic: hyperthyroidism, adrenal insufficiency, diabetes mellitus, hypercalcemia.⁶
• Neurologic: dysphagia from oropharyngeal or esophageal dysmotility, cranial nerve lesions, post-stroke swallowing dysfunction.⁶
• Oncologic and infectious: occult malignancy, chronic infection, HIV-associated wasting.⁶
• Food allergy or anaphylaxis history producing rational avoidance.^6,13

Assessment is multidisciplinary by default. The clinician's first job is to determine whether the patient is medically stable; the second is to characterize the driver(s); the third is to map functional and nutritional impact.^1,15

Interview approach

• Develop a chronological feeding history from infancy, including breastfeeding, weaning, introduction of textures, and any tube-feeding or surgical history.³
• Catalogue current accepted foods, rejected foods, and patterns of expansion or narrowing over time.^1,4
• Probe explicitly for weight-and-shape concern using open and closed questions; ask about mirror checking, body checking, and goals around weight.^1,13
• Identify discrete triggering events (choking, vomiting, allergic reaction, illness) and assess for fear, hypervigilance, and anticipatory anxiety around eating.^1,11
• Screen for autism spectrum disorder, ADHD, anxiety disorders, OCD, and depression.^2,4,7

Mandatory history elements

• Growth trajectory (plotted height, weight, BMI, and z-scores in pediatric patients).¹⁵
• Dietary recall sufficient to estimate energy and key micronutrient intake.¹⁵
• Use of oral nutritional supplements or enteral feeding.^13,15
• Functional impact on school, work, family meals, social activities.^1,13

Physical exam and medical workup

• Vitals including supine and standing heart rate and blood pressure, temperature, and growth parameters.¹⁵
• Signs of malnutrition: muscle wasting, lanugo, cool extremities, delayed capillary refill, edema, gingival changes, pallor.^15-16
• Targeted screening labs: CBC, electrolytes including phosphate and magnesium, glucose, BUN/creatinine, liver enzymes, TSH, vitamin D, vitamin B12, folate, iron studies, prealbumin or albumin.^15-16
• Vitamin A, vitamin C, vitamin E, zinc, copper, and thiamine when intake is severely narrow or signs of specific deficiency are present.¹⁶
• EKG when bradycardic, electrolyte-disturbed, or severely malnourished; bone density (DXA) for prolonged amenorrhea or severe undernutrition.¹⁵

Validated rating scales

• Pica, ARFID, and Rumination Disorder Interview (PARDI) — semi-structured diagnostic interview covering all three drivers.¹⁷
• Nine-Item ARFID Screen (NIAS) — brief self-report identifying the three-driver phenotype.¹⁸
• Eating Disorder Examination (EDE) — used to actively rule out weight-and-shape concern, not to diagnose ARFID.¹

What not to order

• Routine extensive GI imaging or endoscopy in the absence of GI red flags is low yield and can prolong avoidance by reinforcing a search for organic disease.^6,8

Treatment is multidisciplinary, sequenced by acuity, and matched to the driver profile. The standard team includes a physician for medical monitoring, a registered dietitian, and a mental health clinician with feeding-disorder expertise; speech-language pathology and occupational therapy are added for oral-motor or sensory issues.^1,15,19

Pharmacotherapy

• No medication is FDA-approved for ARFID.^1,20
• Limited evidence suggests mirtazapine may improve weight gain, appetite, and anxiety in pediatric and young adult ARFID, primarily from open-label and case-series data.^20-21
• Some experts recommend low-dose olanzapine for severe low-interest or anxiety-driven presentations not responding to first-line interventions, though high-quality evidence is lacking.^20,22
• SSRIs may be useful for prominent anxiety, OCD features, or comorbid depression but have not shown specific benefit for ARFID-related restriction.^20,22
• Cyproheptadine has historical use as an appetite stimulant in pediatric feeding difficulties; evidence in ARFID is limited.²⁰

Psychotherapy

• Cognitive-behavioral therapy for ARFID (CBT-AR) is a manualized 20-30 session protocol adaptable for children, adolescents, and adults, targeting each driver with exposure, behavioral activation around eating, and nutrition coaching.^19,23
• Family-based treatment for ARFID (FBT-ARFID) adapts the Maudsley model, with parents leading nutritional rehabilitation and gradual expansion of accepted foods; evidence is early but promising in younger children.²⁴
• Behavioral feeding therapy with operant principles (escape extinction, differential reinforcement) is standard in pediatric feeding programs for severe early-onset cases, often in intensive day-program settings.^3,19
• Exposure-based approaches for fear-of-consequence presentations resemble specific-phobia treatment, with graded exposure to feared foods, textures, and bodily sensations.^19,23

Neuromodulation

• There is no established role for ECT, rTMS, or other neuromodulation modalities in ARFID; case reports are insufficient to support clinical use.^1,20

Adjunctive

• Nutritional rehabilitation: caloric prescription targeted to weight restoration or maintenance, with structured meal plans and oral nutritional supplements as bridges.^15,19
• Enteral feeding (nasogastric or gastrostomy) when oral intake cannot meet needs; weaning protocols are deliberate and behaviorally informed to avoid reinforcing oral aversion.^3,15
• Higher levels of care (medical hospitalization, partial hospitalization, residential) follow standard eating-disorder admission criteria adapted for the ARFID population — most ARFID admissions are for medical stabilization rather than weight restoration alone.¹⁵
• Treatment of comorbid anxiety, autism spectrum disorder, and functional GI disorders in parallel rather than sequentially.^7-8

Untreated ARFID carries real medical risk, and the treatment evidence base remains thin. The harms picture has two layers: harms of the disorder itself and limitations of what we can confidently recommend.^1,15

Harms of the disorder

• Faltering growth and pubertal delay in pediatric patients.^1,15
• Specific micronutrient deficiency syndromes — scurvy, optic neuropathy, peripheral neuropathy, rickets, anemia.^6,16
• Bradycardia, hypotension, and electrolyte disturbance from chronic undernutrition.¹⁵
• Psychosocial impairment, school refusal, social isolation, and family conflict.^1,4
• Dependence on enteral feeding when oral intake cannot be sustained.^3,15

Harms of treatment

• Refeeding syndrome during nutritional rehabilitation of severely malnourished patients.^15,25
• Operant-based feeding programs in pediatric settings can produce short-term distress; historic protocols using physical prompts are no longer standard.^3,19
• Off-label pharmacotherapy carries class-specific risks without robust efficacy data, including metabolic and EPS effects from olanzapine and pediatric activation/suicidality concerns with SSRIs.^20,22

Limitations of the evidence base

• Most studies are small, single-site, open-label, or pre-DSM-5 in nomenclature; head-to-head RCTs against active comparators are uncommon.^1,20
• Heterogeneity of the three-driver phenotype limits generalization across trials.^1,9
• Long-term outcome data (5+ years) are sparse; reported follow-up is typically 6-24 months.^1,4
• Adult ARFID is under-represented in the evidence base; most trials enroll children and adolescents.^1,5

ARFID intersects with development and comorbidity in ways that shape both presentation and management. Pediatric, autistic, and medically complex patients form the bulk of the clinical population.^1,7,15

Pediatric

• Faltering growth and pubertal delay are the dominant medical concerns; growth charts are essential.¹⁵
• Family-based and behavioral approaches predominate; parents are direct agents of change.^3,24
• School-based and feeding-team coordination is often necessary for severe cases.^3,19

Adolescent and adult

• Adolescents may decompensate around school transitions, peer-related meal contexts, or loss of accepted foods.^1,4
• Adults present with chronic selectivity now causing functional impairment or with post-event fear-based subtypes following choking, vomiting, or medical illness.^1,5-6
• CBT-AR is the most developed psychotherapy in this age range.^19,23

Comorbid autism spectrum disorder

• Sensory-based subtype predominates; treatment incorporates sensory accommodation, predictable food presentation, and slower exposure ladders.^7,19
• Standard exposure approaches may need extensive adaptation; involvement of occupational therapy with sensory expertise is common.^7,19

Perinatal

• Pregnancy can exacerbate restriction (nausea, food aversions) and amplify fear-of-consequence avoidance.^1,5
• Multidisciplinary management with obstetrics is required; data specific to ARFID in pregnancy are very limited.^1,5

Medically complex patients

• Comorbid disorders of gut-brain interaction, EDS-related dysautonomia, and prior tube-feeding histories complicate both diagnosis and treatment.^6,8
• Coordinated care with gastroenterology, motility specialists, and feeding therapists improves outcomes; sequential rather than parallel management is a common failure mode.^6,8

Cultural considerations

• Culturally normative selectivity (religious, ethical, or dietary practices) is excluded by Criterion B and should not be pathologized.¹³
• Access to multidisciplinary feeding teams is uneven, and ARFID may be missed or misclassified as picky eating in primary care.^1,15

Course data for ARFID are limited and most reflect pediatric cohorts. The disorder can remit, persist, or evolve into another eating disorder, particularly when adolescent body-image concerns emerge against a backdrop of longstanding restriction.^1,4

Course patterns

• Pediatric-onset selectivity: many children improve with intervention; a subset remain symptomatic into adolescence and adulthood.^3-4
• Fear-based subtype after a discrete event: often responds well to exposure-based treatment, with shorter time-to-remission than chronic sensory subtypes.^1,11
• Evolution to anorexia nervosa: a recognized transition, especially in adolescent girls with longstanding restriction who develop weight or shape concerns.^2,4

Response and remission

• Open-trial response rates to CBT-AR are encouraging but not yet replicated in large RCTs; reported response is typically 50-70% across small samples.^19,23
• Weight restoration is achievable in the majority of medically compromised pediatric patients with appropriate multidisciplinary care.^15,19
• Dietary variety often improves more slowly than weight, and full remission may require sustained outpatient work.^19,23

Mortality and morbidity

• Mortality data specific to ARFID are limited; deaths are reported from medical complications of severe malnutrition.^1,15
• Long-term morbidity includes persistent micronutrient deficiency, growth stunting, osteopenia, and psychosocial impairment.^15-16

ARFID can produce medical emergencies indistinguishable from those of severe anorexia nervosa; admission decisions follow standard eating-disorder criteria with one major difference — restoration of body-image disturbance is not a treatment target.¹⁵

Hospitalization criteria

• Heart rate below 50 bpm during the day or 45 bpm at night; orthostatic changes; systolic BP below 80-90 mmHg.¹⁵
• Electrolyte derangement, especially hypophosphatemia, hypokalemia, or hypomagnesemia.^15,25
• BMI or weight-for-height below 75% of expected, or rapid weight loss.¹⁵
• Failure of outpatient nutritional rehabilitation; need for enteral feeding initiation.¹⁵
• Acute medical complication of malnutrition (cardiac, neurologic).¹⁵

Suicide and safety

• Suicidality is less prevalent than in anorexia nervosa or bulimia nervosa but should be assessed in every patient with chronic illness burden, comorbid depression, or autism.^2,4
• Agitation and severe distress around meals can occur, particularly in pediatric behavioral programs; environmental modification and behavioral analysis precede pharmacologic intervention.^3,19

ARFID is young as a diagnosis, and several clinically consequential questions remain open. The bulk of disagreement concerns phenotyping, treatment selection, and the boundary with neurodevelopmental conditions.^1,9

Phenotyping and subtypes

• The three-driver model is clinically useful but does not exhaust the phenotype; mixed presentations are the rule, and DSM-5-TR does not formalize subtypes.^1,9,13
• Some experts argue that ARFID is best conceived as a spectrum overlapping autism spectrum disorder and somatic-symptom presentations, while others favor preserving it as a distinct feeding disorder.^7,9

Treatment selection

• The optimal first-line psychotherapy in adolescents and adults is not established; CBT-AR has the most data, but family-based and intensive behavioral approaches are competitive in younger children.^19,23-24
• Pharmacotherapy lacks an FDA-approved option, and the role of mirtazapine and olanzapine remains based on open-label and case-series data; randomized trials are limited but in progress.^20-21

Boundary with autism spectrum disorder

• When selective eating in autism causes functional impairment, whether a separate ARFID diagnosis adds clinical value or merely duplicates the autism formulation is debated.^7,13
• DSM-5-TR explicitly allows the dual diagnosis when restriction warrants independent attention; clinicians vary in how often they apply it.^7,13

Service organization

• ARFID fits awkwardly into adult eating-disorder services oriented around weight-and-shape pathology and into pediatric feeding programs oriented around early childhood; specialized ARFID pathways are emerging but unevenly available.^1,15

• ARFID restriction is not driven by concerns about weight, shape, or body image — this distinguishes it from anorexia nervosa.¹³
• DSM-5-TR Criterion A requires significant weight loss or faltering growth, significant nutritional deficiency, dependence on enteral feeds or oral supplements, or marked psychosocial impairment.¹³
• ARFID and anorexia nervosa are mutually exclusive in DSM-5-TR; weight-and-shape-driven restriction defaults to anorexia nervosa.¹³
• The three clinical drivers are low interest in eating, sensory-based avoidance, and fear of aversive consequences such as choking or vomiting.^1,9
• Compared with anorexia nervosa, ARFID has earlier onset, more balanced sex ratio, and higher rates of autism spectrum disorder and ADHD comorbidity.^2,4,7
• No medication is FDA-approved for ARFID; mirtazapine has the most supportive open-label data for weight gain and appetite.^20-21
• CBT-AR is the most studied manualized psychotherapy, with versions for children, adolescents, and adults.^19,23
• Family-based treatment adapted for ARFID is used in younger children, modeled on the Maudsley approach.²⁴
• Specific micronutrient deficiency syndromes — scurvy, optic neuropathy, rickets, anemia — can occur in ARFID despite normal weight and require explicit screening.^6,16
• Refeeding syndrome with hypophosphatemia, hypokalemia, hypomagnesemia, and thiamine deficiency is a hospitalization risk; supplement thiamine before carbohydrate loading.^15,25
• The Nine-Item ARFID Screen (NIAS) and PARDI are validated tools for ARFID assessment.^17-18
• ICD-11 includes ARFID under feeding and eating disorders with conceptually similar criteria to DSM-5-TR.¹⁴
• A discrete choking or vomiting event commonly triggers fear-of-consequence ARFID, which responds well to exposure-based treatment.^1,11
• Hospitalization criteria for ARFID mirror those for anorexia nervosa: bradycardia under 50 bpm, orthostasis, BMI below 75% expected, electrolyte derangement, or failure of outpatient care.¹⁵
• ARFID can evolve into anorexia nervosa during adolescence when body-image concerns emerge in patients with longstanding restriction.^2,4

No external funding. No conflicts of interest declared. Peer-review status: pending.